Case studies of categorical data-derived adjustment factors

Human and Ecological Risk Assessment (HERA)

Volumn 7, Issue 1, 2001, Pages 61-105

  Naumann, Bruce D ^a   Silverman, Keith C ^a   Dixit, Rakesh ^a   Faria, Ellen C ^a   Sargent, Edward V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acceptable daily intake; Occupational exposure limit; Reference dose; Risk assessment; Safety factors; Tolerable intake; Toxicodynamics; Toxicokinetics; Uncertainty factors

Indexed keywords

EID: 23044526676     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Anastasio GD, Robinson MD, Little JM, et al. 1992. A Comparison of the gastrointestinal side effects of two forms of erythromycin. J Family Pract 35 (5):517-23
2. th ed, pp 617-57. McGraw Hill, NY
3. Arnadottir M, Eriksson L, Thysell H et al. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methtylglutaryl-Coemzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65:410-3 Baldessarini RJ. 1989. Current status of antidepressants: Clinical pharmacology and therapy. J Clin Psychiatry 50 (4):117-26
4. Barclay ML, Duffull SB, Begg EJ, et al. 1995. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. Aust NZ J Med 25: 230-5
5. Baum C, Kennedy DL, and Forbes MB. 1985. Utilization of nonsteroidal anti-inflammatory drugs. Arthrit Rheumatol 28:686-92
6. Baumann P, Nil R, Souche A, et al. 1996. A double-blind placebo controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients. J Clin Psychopharmacol 16:307-14
7. Bertilsson L. 1995. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 29:192-209
8. Bonhomme N and Esposito E. 1998. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: a review. J Clin Psychopharmacol 18 (6):447-54
9. Bouchard JM, DelaunayJ, Delisle JP, et al. 1987. Citalopram versus maprotiline: A controlled clinical multicentre trial in depressed patients. Acta Psychiat Scand 76:583-92
10. Braithwaite RA, Goulding R, Theano G, et al. 1972. Plasma concentration of amitriptyline and clinical response. Lancet 1:1297-300
11. Burnier M and Biollaz J. 1992. Pharmacokinetic optimization of angiotensin converting enzyme (ACE) inhibitor therapy. Clin Pharmacokinet 22:375-84
12. Carter BL, Woodhead JC, Cole KJ, et al. 1987. Gastrointestinal side effects with erythromycin preparations. Drug Intell Clin Pharm 21:734-8
13. th ed, pp 1029-56. McGraw Hill, NY